EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Advances In Immunotherapy-Emerging Treatment Paradigms for Cancer

Amaira Goyal

International Journal of Scientific Research in Science and Technology · 11.07.2025 · 12 (4) · 239-246

DOI: 10.32628/ijsrst251280 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Scientific Research in Science and Technology, online erschienen am 11.07.2025. Verfasst von Amaira Goyal. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lung cancer predominantly comprises non-small cell lung cancer (NSCLC), which accounts for a large portion of cancer cases and remains a leading cause of cancer- related mortality worldwide. Traditional chemotherapy provides limited benefit and is associated with significant toxicity, highlighting the need for more effective and targeted treatment such as monoclonal antibodies.

Objective

The aim of this study to evaluate the effectiveness, quality of life effects, and adverse event profile of nivolumab, a PD-1 immune checkpoint inhibitor, compared to standard first-line therapy in patients with advanced NSCLC.

Methods

A randomized controlled trial includes 60 patients diagnosed with stage III and IV NSCLC. Patient are assigned to receive either nivolumab (240 mg i.v biweekly) (Group A) or platinum-based chemotherapy (Group B). Tumor size, quality of life, and side effects are assessed over a 12- week period using imaging and clinical evaluation.

Results

Tumor size reduces by 40% in Group A and 25% in Group B. Quality of life scores for Group A increased from 60 to 70, while Group B values declined from 60 to 52. Group A exhibited fewer and less severe adverse effects than Group B, with no instances of Grade 4 toxicity recorded in Group A, in contrast to two cases of Grade 4 toxicity in Group B.

Conclusion

The study's findings indicate that, unlike conventional chemotherapy protocols, nivolumab exhibited more efficacy and safety, favorably affecting tumor response and improving patient's quality of life while minimizing treatment-related side effects. This is a crucial therapeutic alternative for advanced NSCLC.

Zitieren

APA

Goyal, A. (2025). Advances In Immunotherapy-Emerging Treatment Paradigms for Cancer. International Journal of Scientific Research in Science and Technology, 12(4), 239-246. https://doi.org/10.32628/ijsrst251280

Vancouver

Goyal A. Advances In Immunotherapy-Emerging Treatment Paradigms for Cancer. International Journal of Scientific Research in Science and Technology. 2025;12(4):239-246. doi:10.32628/ijsrst251280

BibTeX
@article{Goyal2025,
  author = {Goyal, Amaira},
  title = {Advances In Immunotherapy-Emerging Treatment Paradigms for Cancer},
  journal = {International Journal of Scientific Research in Science and Technology},
  year = {2025},
  volume = {12},
  number = {4},
  pages = {239--246},
  doi = {10.32628/ijsrst251280}
}
Kostenlos starten →